Piper Sandler
VC Fund
Aberdeen, United Kingdom
Piper Sandler is a leading middle-market investment bank. Our advisory teams provide unparalleled guidance to clients by combining deep product and sector expertise with ready access to global capital.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Piper Sandler invests in
Stages Piper Sandler invests in
Countries Piper Sandler invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dion Albanese
|
|||
Tyler Griffith
|
|||
Chad Abraham
|
|||
|
Stephen Glassgold
|
|||
Timothy Carter
|
Investment Focus
Industry
- Biotechnology 5 (63%)
- Life Science 4 (50%)
- Biopharma 3 (38%)
- Artificial Intelligence 2 (25%)
- FinTech 1 (13%)
Stage
- Series B 5 (63%)
- Venture - Series Unknown 2 (25%)
- Series C 1 (13%)
Country
- United States 7 (88%)
- United Kingdom 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Dion Albanese
Managing Director at Piper Sandler
|
Managing Director at Piper Sandler | Total investments: 0 | Find email | |
|
Tyler Griffith
Vice President of Investment Banking
|
Vice President of Investment Banking | Total investments: 0 | Find email | |
|
Chad Abraham
CEO
|
CEO | Total investments: 0 | Find email | |
|
Stephen Glassgold
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
|
Timothy Carter
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Infinicept
|
Infinicept provides all of the technology and professional services that companies need to launch as a payment facilitator. This gives Infinicept's customers the ability to control the payments portion of their platform, allowing them to deliver an improved overall product, monetize their payments, and build deeper relationships with theircustomers. Infinicept's agnostic technology platform allows companies to become payment facilitators using any bank, gateway, or processor. Started by payments industry veterans and Payment Facilitator consultants Todd Ablowitz and Deana Rich, Infinicept offers infinite acceptance possibilities for a market that is estimated to top $4.4 billion by 2021. | $23M / Venture - Series Unknown / May 11, 2022 | |
Arbor Biotechnologies
|
Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases. The company utilizes artificial intelligence and high-throughput screening to discover and optimize novel gene-editing systems. Its research focuses on expanding the CRISPR-based gene editing toolbox for therapeuticapplications. Arbor aims to develop treatments for rare and complex diseases by engineering precise and efficient genetic modifications. | $215M / Series B / Nov 09, 2021 | |
Shoreline Biosciences
|
Shoreline Biosciences is a biomedical company intended to establish immunotherapies for seriously ill patients. Its proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cellsto improve anti-cancer activity. The company was founded in 2020 and is headquartered in La Jolla, CA, USA. | $140M / Series B / Nov 02, 2021 | |
Sonoma Biotherapeutics
|
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneersin Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies. | $265M / Series B / Aug 04, 2021 | |
Artios Pharma
|
Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a uniquepartnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK. | $152.7M / Series C / Jul 27, 2021 | |
Graylog
|
Graylog is an AI-powered SIEM and log management software. It combines scalable log management with explainable AI that summarizes dashboards, prioritizes real risks, and automates investigation workflows. Its products include Graylog Security, Enterprise, API Security, and Open software. | $18M / Venture - Series Unknown / Jun 24, 2021 | |
Mike's Hot Honey
|
Mike’s Hot Honey is a food and beverage company that offers a chili, pepper-infused honey. The spicy Hot Honey is a delicious pairing with a wide variety of foods including pizza, chicken, ribs, biscuits, salads, fruits, cheeses, and even ice cream. The company was founded in 2010 and headquartered in Brooklyn, New York. | $4.9M / Series B / Jul 01, 2020 | |
Shattuck Labs
|
Shattuck is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC) platform, a novel class of dual-function fusion proteins with applications in oncology and autoimmune disease. The company’s lead program, SL-279252 (PD1-Fc-OX40L), is being studied in a Phase I trial in collaboration with TakedaPharmaceuticals.Its technology focuses on immuno-oncology research targeted towards patients with many cancer types, including melanoma, lung, and bladder, by endowing one molecule with multiple functions, with applicability across the entire spectrum of human disease that enables medical researchers to find a quick and painless detection of malignancy for later-stage cancer patients. | $118M / Series B / Jun 15, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Piper Sandler invest in?
Piper Sandler invests primarily in Biotechnology, Life Science and Biopharma startups, most often at Series B and Venture - Series Unknown stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Piper Sandler?
Public channels for Piper Sandler include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Piper Sandler?
The team at Piper Sandler includes Dion Albanese (Managing Director at Piper Sandler), Tyler Griffith (Vice President of Investment Banking) and Chad Abraham (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
